Table 2 In-hospital data before and after Propensity-Score Matching.
Characteristic | Before matching | After matching | ||||
|---|---|---|---|---|---|---|
AT group (n = 117) | RT group (n = 421) | p value | AT group (n = 117) | RT group (n = 117) | p value | |
cTnI at admission (ng/mL) | 39.1 (10.1, 85.8) | 26.0 (5.4, 50) | 0.010 | 39.1 (10.1, 85.8) | 48.2 (6.8, 88) | 0.724 |
cTnI peak (ng/mL) | 54.5 (26.9, 88) | 45.8 (13.2, 66.8) | 0.000 | 54.5 (26.9, 88) | 65.0 (23.1, 107.8) | 0.602 |
CK-MB at admission (ng/mL) | 185.8 (73.8, 291.9) | 133.9 (40.3, 279.9) | 0.044 | 185.8 (73.8, 291.9) | 126.7 (42.7, 241.1) | 0.031 |
CK-MB peak (ng/mL) | 200.1 (105.2, 336.9) | 173 (57.9, 338.7) | 0.124 | 200.1 (105.2, 336.9) | 161.1 (60.2, 273.1) | 0.034 |
Hemoglobin (g/L) | 140.6 ± 14.5 | 135.4 ± 21.0 | 0.003 | 140.6 ± 14.5 | 139.5 ± 19.3 | 0.631 |
eGFR (mL/min/1.73 m2) | 81.6 ± 22.5 | 76.6 ± 22.6 | 0.036 | 81.6 ± 22.5 | 82.9 ± 20.3 | 0.629 |
TC (mmol/L) | 4.77 ± 1.16 | 4.70 ± 1.21 | 0.577 | 4.77 ± 1.16 | 4.92 ± 1.34 | 0.345 |
HDL (mmol/L) | 1.21 ± 0.33 | 1.20 ± 0.32 | 0.815 | 1.21 ± 0.33 | 1.23 ± 0.30 | 0.630 |
LDL (mmol/L) | 2.59 ± 0.78 | 2.60 ± 0.87 | 0.933 | 2.59 ± 0.78 | 2.56 ± 0.82 | 0.718 |
INR | 1.14 ± 0.38 | 1.18 ± 0.55 | 0.440 | 1.14 ± 0.38 | 1.12 ± 0.27 | 0.654 |
BNP (pg/mL) | 109 (40.8, 276.3) | 159.5 (70.3, 472) | 0.001 | 109 (40.8, 276.3) | 137.0 (68.8, 346.5) | 0.032 |
Aspirin (%) | 114 (97.4) | 388 (92.2) | 0.043 | 114 (97.4) | 113 (96.6) | 1.000 |
P2Y12 inhibitor (%) | 114 (97.4) | 386 (91.7) | 0.032 | 114 (97.4) | 111 (94.9) | 0.499 |
PPI (%) | 69 (59.0) | 252 (60.0) | 0.841 | 69 (59.0) | 63 (53.8) | 0.429 |
Statin (%) | 114 (97.4) | 387 (91.9) | 0.037 | 114 (97.4) | 111 (94.9) | 0.499 |
ACEi or ARB (%) | 81 (69.2) | 272 (64.6) | 0.352 | 81 (69.2) | 78 (66.7) | 0.674 |
β-blocker (%) | 91 (77.8) | 286 (67.9) | 0.040 | 91 (77.8) | 76 (65.0) | 0.030 |
MRA (%) | 17 (14.5) | 74 (17.6) | 0.437 | 17 (14.5) | 15 (12.8) | 0.704 |
Low molecular heparin (%) | 4 (3.4) | 15 (3.6) | 0.940 | 4 (3.4) | 3 (2.6) | 1.000 |
GP IIb/IIIa inhibitor (%) | 89 (76.1) | 218 (51.8) | 0.000 | 89 (76.1) | 94 (80.3) | 0.429 |
LVEF (%) | 52.9 ± 8.84 | 53.5 ± 8.60 | 0.510 | 52.9 ± 8.84 | 53.6 ± 9.19 | 0.567 |
TIMI flow grade 3 after PCI | 105 (89.7) | 366 (86.9) | 0.416 | 105 (89.7) | 104 (88.9) | 0.832 |
Lengh of stay (days) | 10.6 ± 4.01 | 11.7 ± 6.39 | 0.020 | 10.6 ± 4.01 | 10.9 ± 5.95 | 0.616 |